2024 Á¦9ȸ Á¶Ç÷¸ð¼¼Æ÷ÀÌ½Ä ¾ÆÄ«µ¥¹Ì : 2024-03-09
±³À°ÀÏÀÚ : 2024-03-09
±³À°Àå¼Ò : ¼¼Á¾´ëÇб³ ´ë¾çAI¼¾ÅÍ AIȦ
±³À°ÁÖÁ¦ : 2024 Á¦9ȸ Á¶Ç÷¸ð¼¼Æ÷ÀÌ½Ä ¾ÆÄ«µ¥¹Ì
ÁÖÃÖ±â°ü : ´ëÇÑÁ¶Ç÷¸ð¼¼Æ÷À̽ÄÇÐȸ
´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ : bmt@kams.or.kr
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀÎ : 150¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 30,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03¿ù 09ÀÏ AIȦ 09:30~10:00 Immnue reconstitution after HCT(hematocrit) ÃÖÀ±¼®(°í·ÁÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ AIȦ 10:00~10:30 Microbiome and HCT(hematocrit) À±»óÀº(¼º±Õ°üÀÇ´ë )
±³À°½Ã°£ 03¿ù 09ÀÏ AIȦ 11:05~11:35 Donor lymphocyte infusion ÀÌÁöÇö(µ¿¾ÆÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ AIȦ 11:35~12:05 Graft versus-Host Disease Á¶Àçö(¿ï»êÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ AIȦ 12:05~12:35 Graft failure °¼ºÇÑ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ AIȦ 13:30~13:55 Prevention and treatment of VOD(Hepatic veno-occlusive disease)/SOS(sinusoidal obstruction syndrome) À±ÀçÈ£(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ AIȦ 13:55~14:20 Blood transfusion before and after HCT(hematocrit) ±Ç¼ø¼º(¿¬¼¼ÀÇ´ë )
±³À°½Ã°£ 03¿ù 09ÀÏ AIȦ 14:20~14:45 GVHD(graft-versus-host disease): °£È£»çÀÇ ÀÌÇØ¿Í °£È£Àû Á¢±Ù ÃÖÇýÁø(»ï¼º¼¿ïº´)
±³À°½Ã°£ 03¿ù 09ÀÏ AIȦ 15:30~15:55 Current landscape in adoptive cellular therapies Á¶´ö(¼º±Õ°üÀÇ´ë )
±³À°½Ã°£ 03¿ù 09ÀÏ AIȦ 15:55~16:20 Experence of adverse events after CAR-T or BiTEs À±´öÇö(¿ï»êÀÇ´ë )
±³À°½Ã°£ 03¿ù 09ÀÏ AIȦ 16:20~16:45 Vaccination after HCT(hematocrit) and CAR-T cell therapy °½ÂÁö(Àü³²ÀÇ´ë )